Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tasly Biopharmaceuticals Co. Ltd.

Division of Tasly Pharmaceutical Co. Ltd.
www.taslyshanghai.com

Latest From Tasly Biopharmaceuticals Co. Ltd.

Venture Funding Deals: Alector, Ascentage, Gossamer And Compass Lead Summer Rounds

Compass raises $132m in Series A as it moves from screening to the clinic, and start-up HotSpot Therapeutics comes out of stealth mode with a $45m Series A financing co-led by Atlas Venture and Sofinnova Partners.

Deals Financing

Asia Deal Watch: Daiichi Sankyo Licenses Glycotope's Gatipotuzumab ADC

Daiichi Sankyo gains worldwide rights to an antibody-drug conjugate version of Glycotope’s gatipotuzumab for various cancers. Also, Tasly buys China rights to Mesoblast's CV candidates and India's Cipla grows in Africa.

Asia Pacific Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Gastrointestinal
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Shanghai Tasly Pharmaceutical Co. Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Tasly Pharmaceutical Co. Ltd.
  • Senior Management
  • Contact Info
  • Tasly Biopharmaceuticals Co. Ltd.
    Shanghai,
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register